What is Sidoti’s Estimate for USNA FY2026 Earnings?

USANA Health Sciences, Inc. (NYSE:USNA) – Equities researchers at Sidoti boosted their FY2026 earnings estimates for USANA Health Sciences in a report released on Thursday, February 19th. Sidoti analyst A. Lebiedzinski now expects that the company will earn $2.00 per share for the year, up from their prior forecast of $1.84. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.66 EPS.

USNA has been the subject of a number of other reports. Zacks Research upgraded USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Saturday. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, USANA Health Sciences presently has a consensus rating of “Reduce” and a consensus target price of $36.00.

USANA Health Sciences Trading Up 0.3%

USNA stock opened at $21.73 on Monday. The firm has a 50-day moving average of $20.73 and a two-hundred day moving average of $23.40. USANA Health Sciences has a 12 month low of $18.48 and a 12 month high of $38.32. The company has a market cap of $397.22 million, a price-to-earnings ratio of 39.51, a PEG ratio of 0.90 and a beta of 0.67.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.19. The firm had revenue of $226.20 million for the quarter, compared to the consensus estimate of $225.96 million. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, insider Joshua Foukas sold 4,461 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $21.34, for a total transaction of $95,197.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.63% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds have recently modified their holdings of USNA. Nantahala Capital Management LLC acquired a new stake in shares of USANA Health Sciences during the 4th quarter worth about $11,485,000. Millennium Management LLC boosted its stake in USANA Health Sciences by 715.7% during the fourth quarter. Millennium Management LLC now owns 285,416 shares of the company’s stock worth $5,603,000 after buying an additional 250,424 shares during the period. Two Sigma Investments LP increased its position in shares of USANA Health Sciences by 349.8% during the third quarter. Two Sigma Investments LP now owns 160,933 shares of the company’s stock valued at $4,434,000 after acquiring an additional 125,158 shares during the last quarter. UBS Group AG increased its position in shares of USANA Health Sciences by 252.3% during the fourth quarter. UBS Group AG now owns 138,334 shares of the company’s stock valued at $2,715,000 after acquiring an additional 99,063 shares during the last quarter. Finally, Tudor Investment Corp ET AL raised its stake in shares of USANA Health Sciences by 354.8% in the 4th quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock valued at $2,153,000 after acquiring an additional 85,570 shares during the period. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.